FDA adds EpiPens to list of drug shortages

The Food and Drug Administration added the EpiPen to its list of drug shortages Wednesday, citing a disruption with the supply.

Along with EpiPens, the FDA added generic versions and Adrenaclick autoinjectors to its drug shortage list. All of these medications are used to treat allergic reactions, some of which can be life-threatening.

According to the FDA Safety and Innovation Act guidelines, the shortages of the EpiPens, its generic versions and Adrenaclick autoinjectors is the result of manufacturing delays. However, the distributor of EpiPens and its generic versions, Mylan, said in a press release that the "product is available and Mylan is currently receiving continual supply from its manufacturing partner."

Impax, or Amneal Pharmaceuticals, manufacturers Adrenaclick autoinjectors, which is also experiencing a shortage.

8 PHOTOS
Most common food allergies to be aware of
See Gallery
Most common food allergies to be aware of

Peanuts and peanut products

(Photo via Shutterstock)

Tree nuts

(Photo by Jeremy Woodhouse via Getty Images)

Cow's milk

(Photo by Igor Skrynnikov via Getty Images)

Eggs

(Photo by Andrew Unangst via Getty Images)

Wheat

(Photo by Roger Dixon via Getty Images)

Soy

(Photo by Vlad Fishman via Getty Images)

Fish

(Photo by Lew Robertson via Getty Images)

Shellfish

(Photo by Alexandra Grablewski via Getty Images)

HIDE CAPTION
SHOW CAPTION
of
SEE ALL
BACK TO SLIDE

Mylan says it is expediting shipment of EpiPens to wholesalers and "supply levels may vary across wholesalers and pharmacies." Although distributed by Mylan, the drug is manufactured by Meridian Medical Technologies, a Pfizer company.

"A few months ago, Mylan informed the FDA of intermittent supply constraints due to manufacturing delays from Pfizer. Since this time, Mylan and Pfizer have remained in close contact with FDA to provide regular updates on the inventory status," the release said.

Pfizer said in a press release it is working to increase production of the medications as quickly as possible.

"Pfizer takes very seriously the importance of EpiPen to everyone who needs it, and we are

working tirelessly to increase production as rapidly as possible," the release said. "We are currently shipping EpiPen, with production increasing over the last few months and anticipated to continue to increase and stabilize over the coming months."

The drug company also asks that customers with a "medically appropriate" supply of unexpired EpiPen be prudent in refilling additional prescriptions during the shortage so others have access to the drug.

Based on this information, an FDA representative told NBC News, the agency expects the shortage to be short term.

7 PHOTOS
EpiPen
See Gallery
EpiPen
FILE PHOTO -- EpiPen auto-injection epinephrine pens manufactured by Mylan NV pharmaceutical company for use by severe allergy sufferers are seen in Washington, U.S. August 24, 2016. REUTERS/Jim Bourg/File Photo
EpiPen auto-injection epinephrine pens manufactured by Mylan NV pharmaceutical company for use by severe allergy sufferers are seen in Washington, U.S. August 24, 2016. REUTERS/Jim Bourg
Boxes of Mylan NV's EpiPen 2-Pak allergy shots sit on display for a photograph at a pharmacy in Princeton, Illinois, U.S., on Friday, Aug. 26, 2016. In response to intense criticism over the past few days, Mylan NV moved Thursday to expand assistance programs that help patients with high out-of-pocket expenses -- but didn't go as far as cutting the treatment's list price. Health insurers and U.S. lawmakers criticized the effort as an attempt to cover a 400 percent price hike that won't make the drug more affordable. Photographer: Daniel Acker/Bloomberg via Getty Images
Mylan NV's logo is displayed on a box of EpiPen 2-Pak allergy shots at a pharmacy in Princeton, Illinois, U.S., on Friday, Aug. 26, 2016. In response to intense criticism over the past few days, Mylan NV moved Thursday to expand assistance programs that help patients with high out-of-pocket expenses -- but didn't go as far as cutting the treatment's list price. Health insurers and U.S. lawmakers criticized the effort as an attempt to cover a 400 percent price hike that won't make the drug more affordable. Photographer: Daniel Acker/Bloomberg via Getty Images
Mylan NV's EpiPen allergy shots sit on display for a photograph in Princeton, Illinois, U.S., on Friday, Aug. 26, 2016. In response to intense criticism over the past few days, Mylan NV moved Thursday to expand assistance programs that help patients with high out-of-pocket expenses -- but didn't go as far as cutting the treatment's list price. Health insurers and U.S. lawmakers criticized the effort as an attempt to cover a 400 percent price hike that won't make the drug more affordable. Photographer: Daniel Acker/Bloomberg via Getty Images
This August 24, 2016 photo taken in Hudson, Wisconsin shows a youngster holding Epipens, that he uses to counteract allergic reactions. A five-fold price hike for EpiPen, which allergy sufferers use to counteract life-threatening reactions, has made Mylan the newest drugmaker to come under attack in the United States for profiteering. Mylan Pharmaceuticals, which holds a near-monopoly position on the epinephrine injectors used by millions against severe allergic attacks, was assailed by two powerful US senators for pumping up the price over six years from $100 to more than $500. That has rendered EpiPens unaffordable to many sufferers -- who must replace them each year -- and is costing the government huge sums to stock schools with them and fund insurance programs which pay for them, the lawmakers said Monday. / AFP / Lucas TRIEB (Photo credit should read LUCAS TRIEB/AFP/Getty Images)
This August 24, 2016 photo taken in Hudson, Wisconsin shows Epipens, used to counteract allergic reactions. A five-fold price hike for EpiPen, which allergy sufferers use to counteract life-threatening reactions, has made Mylan the newest drugmaker to come under attack in the United States for profiteering. Mylan Pharmaceuticals, which holds a near-monopoly position on the epinephrine injectors used by millions against severe allergic attacks, was assailed by two powerful US senators for pumping up the price over six years from $100 to more than $500. That has rendered EpiPens unaffordable to many sufferers -- who must replace them each year -- and is costing the government huge sums to stock schools with them and fund insurance programs which pay for them, the lawmakers said Monday. / AFP / Lucas TRIEB (Photo credit should read LUCAS TRIEB/AFP/Getty Images)
HIDE CAPTION
SHOW CAPTION
of
SEE ALL
BACK TO SLIDE

Copyright 2017 U.S. News & World Report

Read Full Story